STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

NCT00088088 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer

Interventions

DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: STA 4783

Sponsor

Synta Pharmaceuticals Corp.